APA

Pena L. D. M., Barohn R. J., Byrne B. J., Desnuelle C., Goker-Alpan O., Ladha S., Laforêt P., Mengel K. E., Pestronk A., Pouget J., Schoser B., Straub V., Trivedi J., Van Damme P., Vissing J., Young P., Kacena K., Shafi R., Thurberg B. L., Culm-Merdek K. & van der Ploeg A. T. (20200601). Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. : Neuromuscular disorders : NMD.

Chicago

Pena Loren D M, Barohn Richard J, Byrne Barry J, Desnuelle Claude, Goker-Alpan Ozlem, Ladha Shafeeq, Laforêt Pascal, Mengel Karl Eugen, Pestronk Alan, Pouget Jean, Schoser Benedikt, Straub Volker, Trivedi Jaya, Van Damme Philip, Vissing John, Young Peter, Kacena Katherine, Shafi Raheel, Thurberg Beth L, Culm-Merdek Kerry and van der Ploeg Ans T. 20200601. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. : Neuromuscular disorders : NMD.

Harvard

Pena L. D. M., Barohn R. J., Byrne B. J., Desnuelle C., Goker-Alpan O., Ladha S., Laforêt P., Mengel K. E., Pestronk A., Pouget J., Schoser B., Straub V., Trivedi J., Van Damme P., Vissing J., Young P., Kacena K., Shafi R., Thurberg B. L., Culm-Merdek K. and van der Ploeg A. T. (20200601). Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. : Neuromuscular disorders : NMD.

MLA

Pena Loren D M, Barohn Richard J, Byrne Barry J, Desnuelle Claude, Goker-Alpan Ozlem, Ladha Shafeeq, Laforêt Pascal, Mengel Karl Eugen, Pestronk Alan, Pouget Jean, Schoser Benedikt, Straub Volker, Trivedi Jaya, Van Damme Philip, Vissing John, Young Peter, Kacena Katherine, Shafi Raheel, Thurberg Beth L, Culm-Merdek Kerry and van der Ploeg Ans T. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. : Neuromuscular disorders : NMD. 20200601.